Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: The ARCTIC-GENE study

European Journal of Clinical Pharmacology

Volumn 71, Issue 11, 2015, Pages 1315-1324

  Collet, Jean Philippe ^a   Hulot, Jean Sébastien ^a   Cuisset, Thomas ^e   Rangé, Grégoire ^b   Cayla, Guillaume ^c   Van Belle, Eric ^d   Elhadad, Simon ^f   Rousseau, Hélène ^g,h   Sabouret, Pierre ^a   O'Connor, Stephen A ^a   Abtan, Jérémie ^a   Kerneis, Mathieu ^a   Saint Etienne, Christophe ⁱ   Barthélémy, Olivier ^a   Beygui, Farzin ^j   Silvain, Johanne ^a   Vicaut, Eric ^g,h   Montalescot, Gilles ^a  

^a Sorbonne Universités   (France)

^b Les Hopitaux de Chartres   (France)

^c DEPARTMENT OF NEUROLOGY   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e TIMONE HOSPITAL   (France)

^f Centre hospitalier de Lagny Marne la Vallee   (France)

^g HÔPITAL LARIBOISIÈRE   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ SERVICE DE DERMATOLOGIE   (France)

^j CAEN UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Antiplatelet therapy; Clopidogrel; Pharmacogenetic; Platelet reactivity; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; TICLOPIDINE;

ADULT; ALGORITHM; ALLELE; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY STENT; DEATH; DRUG ELUTING STENT; FEMALE; GAIN OF FUNCTION MUTATION; GENETIC SCREENING; GENOTYPE; HEART INFARCTION; HUMAN; HUMAN CELL; IMPLANTATION; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENT IMPLANTATION; THROMBOCYTE FUNCTION; TREATMENT RESPONSE; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; BLOOD CLOTTING PARAMETERS; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; STENT; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT OUTCOME;

AGED; CYTOCHROME P-450 CYP2C19; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; STENTS; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84945489581     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1917-9     Document Type: Article

References (30)

1. Authors/Task Force members, Windecker S, Kolh P, et al. (2014) 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35(37):2541-2619
2. Angiolillo DA, Fernandez-Ortiz A, Bernardo E, et al. (2007) Variability in individual responsiveness to clopidogrel clinical implications, management, and future perspectives. J Am Coll Cardiol 49:1505-1516
3. Kazui M, Nishiya Y, Ishizuka T, et al. (2009) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38(1):92-99
4. Cayla G, Hulot J-S, O'Connor SA, et al. (2011) Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA J. Am. Med. Assoc. 306(16):1765-1774
5. Collet JP, Hulot JS, Montalescot G (2009) Cytochrome P450 2C19 polymorphism and clopidogrel after MI. Lancet 373:1172-1173
6. Mega JL, Simon T, Collet J-P, et al. (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA J. Am. Med. Assoc. 304(16):1821-1830
7. Collet J-P, Cuisset T, Rangé G, et al. (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367(22):2100-2109
8. Price MJ, Berger PB, Teirstein PS, et al. (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305(11):1097-1105
9. Trenk D, Stone GW, Gawaz M, et al. (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 59(24):2159-2164
10. Campo G, Parrinello G, Ferraresi P, et al. (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention. J Am Coll Cardiol 57:2474-2483
11. Stone GW, Witzenbichler B, Weisz G, et al. (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382(9892):614-623
12. Aradi D, Storey RF, Komocsi A, et al. (2013) Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 62(24):2261-2273
13. Collet JP, Cayla G, Cuisset T, et al. (2011) Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. Am Heart J 161(1):5-12 e5
14. Montalescot G, Rangé G, Silvain J, et al. (2014) High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: a landmark analysis of the ARCTIC study. Circulation 129(21):2136-2143
15. Montalescot G, Sechtem U, Achenbach S, et al. (2013) 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34(38):2949-3003
16. Collet JP, Hulot JS, Anzaha G, et al. (2011) High doses of clopidogrel to overcome genetic resistance (the CLOVIS-2 study). J Am Coll Cardiol Intv 4:392-402
17. Hulot JS, Collet JP, Silvain J, et al. (2010) Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19∗2 loss-of-function allele or proton pump inhibitor co-administration: a systematic meta-analysis. J Am Coll Cardiol 56(2):134-143
18. http://www.fda.gov/Drugs/DrugSafety/Postmarket FDSC reduced effectiveness of P (clopidogrel) in patients who are poor metabolizers of the drug. A at:, DrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed April 28 2010. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug.
19. Roberts JD, Wells GA, Le May MR, et al. (2012) Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial: the RAPID GENE trial. Lancet 379(9827):1705-1711. doi: 10.1016/S0140-6736 (12)60161-5
20. Mega JL, Hochholzer W, Frelinger 3rd AL, et al. (2011) Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306(20):2221-2228
21. Frelinger 3rd AL, Bhatt DL, Lee RD, et al. (2013) Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 61(8):872-879
22. Price MJ, Murray SS, Angiolillo DJ, et al. (2012) Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol 59(22):1928-1937
23. Fontana P, Cattaneo M, Combescure C, Reny J-L. Tailored thienopyridine therapy: no urgency for CYP2C19 genotyping. J Am Heart Assoc. 2013;2(2):e000131-e000131.
24. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D (2011) Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 343:d4588
25. Paré G, Mehta SR, Yusuf S, et al. (2010) Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 363(18):1704-1714
26. Bhatt DL, Paré G, Eikelboom JW, et al. (2012) The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J 33(17):2143-2150
27. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP (2011) CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA J Am Med Assoc 306(24):2704-2714
28. Kerneis M, Silvain J, Abtan J, et al. (2013) Switching acute coronary syndrome patients from prasugrel to clopidogrel. JACC Cardiovasc. Interv. 6(2):158-165
29. Tantry US, Bonello L, Aradi D, et al. (2013) Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62(24):2261-2273
30. COLLET J, Kerneis M, Hulot JS, et al.; Point-of-care genetic profiling in acute coronary syndrome: the GAMMA Study. JESFC Paris 2015. Abstract 0466.